Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 1:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 166 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: DM Clear all
Recruiting Phase 2 Interventional

MANAGe-DM: Novel Nurse Case Management to Improve Diabetes Outcomes in Formerly Incarcerated Black Men

NCT06031428
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
MANAGe-DM - novel nurse case management, Monthly Educational Mailing
Behavioral
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 28, 2026, 1:19 PM EDT
Completed Phase 2 Interventional Results available

Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Residual Schizophrenia

NCT02477670
View directory record Official record
Conditions
Schizophrenia
Interventions
AVP-786, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
17
States / cities
Cerritos, California • Garden Grove, California • National City, California + 14 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 28, 2026, 1:19 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Combining Shockwave Therapy and Platelet Rich Plasma to Treat Erectile Dysfunction in Diabetic Men (COCKTAIL-DM)

NCT05525572
View directory record Official record
Conditions
Erectile Dysfunction With Diabetes Mellitus
Interventions
Shockwave Therapy (SWT), Autologous Platelet-Rich Plasma (PRP)
Device · Drug
Lead sponsor
University of Miami
Other
Eligibility
30 Years to 80 Years · Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 28, 2025 · Synced Oct 28, 2026, 1:19 PM EDT
Terminated No phase listed Observational

Assessing Clinical Endpoints and Biomarkers in Myotonic Dystrophy Type-1 and Type 2 (ASCEND-DM)

NCT03867435
View directory record Official record
Conditions
Myotonic Dystrophy Type-1, Myotonic Dystrophy Type-2
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
11 Years to 70 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 28, 2026, 1:19 PM EDT
Completed Not applicable Interventional

Sitagliptin Treatment in Patients With Type 2 DM After Kidney Transplant

NCT00466518
View directory record Official record
Conditions
Kidney Transplant, Type 2 Diabetes
Interventions
Administration of sitagliptin
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
19 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 28, 2026, 1:19 PM EDT
Recruiting Phase 2 Interventional

A Phase II, Placebo Controlled, Clinical Trial of Topical TolaSure Targeting Aggregated Mutant Keratin in Epidermolysis Bullosa Simplex

NCT07027345
View directory record Official record
Conditions
Epidermolysis Bullosa Simplex
Interventions
5% TolaSure Topical Gel, Topical Placebo Gel
Drug
Lead sponsor
BioMendics, LLC
Industry
Eligibility
2 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Palo Alto, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 28, 2026, 1:19 PM EDT
Not yet recruiting Phase 1 Interventional

BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Autoimmune Disease

NCT07729995
View directory record Official record
Conditions
Rheumatoid Arthritis (RA), Systemic Lupus Erthematosus (SLE), Dermatomyositis (DM), Systemic Sclerosis (SSc)
Interventions
LMY-922
Biological
Lead sponsor
Luminary Therapeutics
Industry
Eligibility
16 Years to 75 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 28, 2026, 1:19 PM EDT
Terminated Not applicable Interventional

Study of a Home Delivered Meal Program on Obese Elderly African American Subjects With Type 2 Diabetes Mellitus (DM)

NCT00743756
View directory record Official record
Conditions
Obesity, Diabetes
Interventions
home-delivered meals, diabetes education for 12 months
Dietary Supplement · Behavioral
Lead sponsor
Emory University
Other
Eligibility
65 Years to 85 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 10, 2014 · Synced Oct 28, 2026, 1:19 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy Registry

NCT00082108
View directory record Official record
Conditions
Myotonic Dystrophy, Facioscapulohumeral Muscular Dystrophy, Muscular Dystrophy, Myotonic Dystrophy Type 1, Myotonic Dystrophy Type 2, Congenital Myotonic Dystrophy, PROMM (Proximal Myotonic Myopathy), Steinert's Disease, Myotonic Muscular Dystrophy
Interventions
Not listed
Lead sponsor
University of Rochester
Other
Eligibility
Not listed
Enrollment
3,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2028
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 28, 2026, 1:19 PM EDT
Terminated No phase listed Observational

Rate of Change of HbA1c (dx/dt) May Predict Progression to Type 2 DM

NCT01315808
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
Not listed
Lead sponsor
Wyckoff Heights Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
542 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Mar 20, 2012 · Synced Oct 28, 2026, 1:19 PM EDT
Terminated Not applicable Interventional Results available

Cinnamon Bark, Water-Soluble Cinnamon Extract, and Metformin for Treatment of Type 2 DM.

NCT01302743
View directory record Official record
Conditions
Diabetes
Interventions
Group 1: Metformin, Group 2: Cinnamon Bark, Group 3: Cinnulin PF
Drug · Dietary Supplement
Lead sponsor
Mike O'Callaghan Military Hospital
Federal
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Nellis Air Force Base, Nevada
Source: ClinicalTrials.gov public record
Updated Jun 26, 2017 · Synced Oct 28, 2026, 1:19 PM EDT
Completed Phase 2 Interventional Results available

A Study of Single and Multiple Doses of Oral Insulin or Placebo in Subjects With Type 2 Diabetes Mellitus

NCT02954601
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
ORMD-0801 (qd), ORMD-0801 (bid), ORMD-0801 (tid), Placebo
Drug · Other
Lead sponsor
Oramed, Ltd.
Industry
Eligibility
20 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Tustin, California
Source: ClinicalTrials.gov public record
Updated Jul 12, 2018 · Synced Oct 28, 2026, 1:19 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Hypoglycemia Associated Autonomic Failure in Type 1 DM, Q2

NCT00592332
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Alprazolam, control group
Drug · Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 45 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 11, 2014 · Synced Oct 28, 2026, 1:19 PM EDT
Completed Phase 2 Interventional Results available

Rituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM)

NCT00106184
View directory record Official record
Conditions
Myositis, Dermatomyositis, Polymyositis, Juvenile Dermatomyositis
Interventions
Rituximab, Placebo
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
5 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
27
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2015 · Synced Oct 28, 2026, 1:19 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Salsalate Therapy to Reduce Insulin Resistance and Cardiovascular Risk

NCT00330733
View directory record Official record
Conditions
Atherosclerosis, Cardiovascular Disease, Inflammation, Insulin Resistance, Noninsulin-dependent Diabetes Mellitus
Interventions
Salsalate, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
21 Years to 75 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 21, 2020 · Synced Oct 28, 2026, 1:19 PM EDT
Completed No phase listed Observational

Mechanisms of Glycemic Improvement After Gastrointestinal Surgery

NCT01025999
View directory record Official record
Conditions
Diabetes Mellitus, Type II
Interventions
No intervention
Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 31, 2016 · Synced Oct 28, 2026, 1:19 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Development of Quantitative Muscle Imaging as a Biomarker of Disease Endpoints in Myotonic Dystrophy

NCT07362875
View directory record Official record
Conditions
Myotonic Dystrophy
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 28, 2026, 1:19 PM EDT
Not yet recruiting Phase 2 Interventional

Mitigating DKA in Type 1 Diabetes for Safe Use of SGLT Inhibitors Using Dual Continuous Ketone and Glucose Monitoring.

NCT07325201
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Chronic Kidney Disease (CKD) With Diabetes Mellitus (DM), Chronic Kidney Disease, Diabetic Ketoacidosis, Ketones
Interventions
Sotagliflozin initiation
Drug
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 28, 2026, 1:19 PM EDT
Completed Not applicable Interventional Results available

Inpatient Diabetes Mellitus (DM) Management With Continuous Glucose Monitoring Devices, a Pilot Study.

NCT02904512
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Continuous glucose Monitoring (CGM) device and Point of Care (POC) blood glucose, Point of Care (POC) blood glucose
Device · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 22, 2021 · Synced Oct 28, 2026, 1:19 PM EDT
Completed Phase 2 Interventional Results available

Ph 2 Trial of Vitamin C & G-FLIP (Low Doses Gemcitabine, 5FU, Leucovorin, Irinotecan, Oxaliplatin) for Pancreatic Cancer

NCT01905150
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
G-FLIP, G-FLIP-DM, Vitamin C
Drug · Dietary Supplement
Lead sponsor
Bruckner Oncology
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Dec 11, 2024 · Synced Oct 28, 2026, 1:19 PM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy of BAF312 in Dermatomyositis

NCT02029274
View directory record Official record
Conditions
Active Dermatomyositis
Interventions
BAF312, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
6
States / cities
Phoenix, Arizona • Los Angeles, California • Orange, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 28, 2026, 1:19 PM EDT
Completed No phase listed Observational

MiniMed Fit Payload Wear Pediatric Study

NCT07675161
View directory record Official record
Conditions
Diabetes (DM), Diabetes (Insulin-requiring, Type 1 or Type 2), Diabetes in Children, Diabetes in Adolescence
Interventions
MiniMed Fit Payload adhesive components
Device
Lead sponsor
Medtronic MiniMed, Inc.
Industry
Eligibility
7 Years to 17 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
5
States / cities
Sacramento, California • Santa Barbara, California • Idaho Falls, Idaho + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 28, 2026, 1:19 PM EDT
Completed Phase 4 Interventional Results available

ENhancing Outcomes Through Goal Assessment and Generating Engagement in Diabetes Mellitus

NCT02910089
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
Shared Decision Making
Behavioral
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
1,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 17, 2019 · Synced Oct 28, 2026, 1:19 PM EDT
Terminated Phase 2 Interventional Results available

TRX4 Monoclonal Antibody in Type 1 Diabetes (T1 DM)

NCT00451321
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Otelixizumab
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years to 45 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
16
States / cities
Birmingham, Alabama • Walnut Creek, California • Aurora, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Oct 28, 2026, 1:19 PM EDT